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Background: Infection with hepatitis E virus (HEV) in immunocompromised patients can lead to severe liver
disease. Treatment options for HEV include peginterferon or ribavirin, routinely also used for the treatment of
hepatitis C virus (HCV) infection.
We determined the prevalence and clinical consequences of HEV in United States (US) based patients who
underwent liver transplantation (LT) for chronic HCV.
Methods: Seroprevalence of HEV in 145 US LT recipients with a history of chronic HCV was determined pre-LT, 1, 3
and 5 years post-LT. All last available samples and all samples in IgM positive patients and post-LT IgG seroconverters
were tested for HEV RNA.
Results: Overall anti-HEV seroprevalence was 42 %. Five patients were HEV IgM positive pre-LT, one patient had IgM
seroconversion post-LT and eight patients had IgG seroconversion post-LT. None of the tested samples were positive
for HEV RNA. Eight out of nine of the post-LT seroconverters had been treated for HCV recurrence before or at the
moment of seroconversion.
Conclusions: LT recipients in the US are at risk of acquiring HEV. Post-LT HCV treatment with interferons and/or
ribavirin may have protected patients against chronic HEV. With the arrival of new direct antiviral agents for the
treatment of HCV and the elimination of peginterferon and ribavirin from HCV treatment regimens, the prevalence
of chronic HEV in this population may rise again.Background
Hepatitis E virus (HEV), an enterically transmitted virus
that is known for causing acute hepatitis, was first
isolated in 1990 [1]. HEV is a non-enveloped virus with
a single-stranded, positive sense RNA genome of ap-
proximately 7,500 base pairs and three partially overlap-
ping open reading frames (ORF 1–3) [2]. Up to date,
there are four genotypes prevalent known to infect
humans. Genotype 1 and 2 are endemic in developing
countries and mainly transmitted through contaminated* Correspondence: a.vandereijk@erasmusmc.nl
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While in most cases HEV infection is usually a self-
limiting disease, in the past years multiple reports have
emerged on immunocompromised patients, especially
solid organ transplant (SOT) recipients, developing
chronic HEV infection [5–7]. Reports on HEV infec-
tions in SOT recipients in the United States are scarce.
Almost all well-defined cohort studies in industrialized
countries on HEV infection in SOT recipients up to
now have been done in Europe and these results
cannot be automatically extrapolated to the situation
in the US due to geographical and demographicle is distributed under the terms of the Creative Commons Attribution 4.0
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transplant candidates in the US showed a pre-transplant
seroprevalence of almost 20 % [8]. Estimates of the sero-
prevalence of HEV in the general population (including
blood donors) in the US are reaching up to 22 % [9–13].
Swine-human contact is seen as an important possible
source for HEV transmission in the US: HEV infection
occurs in more than 80 % of some pig herds in the US
[14] and HEV RNA has been found in pig feces on
multiple US farms and pig livers sold in local US gro-
cery stores [15–17]. Veterinarians working with swine
are 1.5 times more likely to be HEV IgG positive than
blood donors from the same area [10]. In US blood
donors, an HEV seroprevalence of up to 22 % has been
reported, making blood transfusions a likely mode of
transmission as well [9–11].
Consequently, SOT recipients in the US are at risk
of acquiring HEV infection. Early detection of HEV
infection in these patients is crucial, since chronic
HEV in SOT recipients can lead to rapid fibrosis and
even cirrhosis [18–20].
Chronic HEV can be adequately managed by dose re-
duction of immunosuppressive medication or treatment
with peginterferon alpha or ribavirin (RBV), compounds
also used for the treatment of hepatitis C virus (HCV)
infection [21–24]. Currently, no studies on HEV infec-
tion in HCV infected SOT recipients are available. On
one hand, there is a risk of development of progressive
or even fulminant liver disease when co-infection with
HEV in these patients occurs. On the other hand,
chronic HEV infection may be less prevalent due to
treatment of HCV.
To gain more insight into the prevalence of hepatitis
E infection in SOT recipients in the US and the influ-
ence of HCV treatment on the incidence and clinical
course of HEV we conducted the current study in a co-
hort of patients with a history of HCV that underwent
a liver transplantation in the Mayo Clinic in Rochester,
Minnesota.
Methods
Patients and samples
From 1997 through 2010 serum samples were prospect-
ively collected according to a standard protocol in
patients with a history of chronic hepatitis C infection
that underwent liver transplantation for end stage liver
disease or hepatocellular carcinoma in the Mayo Clinic
in Rochester, Minnesota (US). No donor organs were
obtained from executed prisoners or other institutional-
ized persons. Samples were collected in 145 patients at
four time points: pre-transplantation (baseline), 1, 3 and
5 years post-liver transplantation and subsequently stored
at −70 °C. Each enrolled subject had consented in future
testing of archived bio-samples. Samples were shipped tothe Erasmus University Medical Center in Rotterdam
(The Netherlands) for hepatitis E testing. The study proto-
col conforms to the ethical guidelines of the 1975 Declar-
ation of Helsinki and was approved by the Institutional
Review Board of the Mayo Clinic in Rochester, Minnesota
(US).
HEV specific antibody detection
First, all collected samples were tested for both HEV spe-
cific IgM and HEV specific IgG with the commercially
available enzyme-linked immunosorbent assay (ELISA)
(Wantai, Beijing, China), used according to the manufac-
turer’s instructions.
HEV-RNA detection
Second, all samples in patients with HEV specific IgM
antibodies and patients with HEV specific IgG serocon-
version post-LT were tested for the presence of HEV
RNA by an internally controlled quantitative real-time
RT-PCR, described previously [6]. The RT-PCR has a
lower limit of detection (95 % hit rate) of 143 IU/ml as
determined by the 1st WHO standard for HEV RNA
NAT-Based assays (6329/10, Paul Ehrlich Institute,
Germany). Finally, all last available samples in the 145
patients were tested for HEV RNA to detect any on-
going active HEV infection at the last follow up point,
since seroconversion in immunocompromised patients
is often delayed and these patients might not have sero-
converted yet.
Results
A total of 370 samples in 145 LT-recipients were avail-
able for analysis. Distribution of samples over time and
serology test results are given in Fig. 1. Baseline charac-
teristics are given in Table 1.
IgG seroconversion
A total of 61 patients (42 %) had HEV specific IgG anti-
bodies at some point from baseline up to last follow up.
Seroprevalence of HEV at baseline was higher in men
compared to women, however, overall seroprevalence
from baseline up to last follow up did not differ between
sexes: N = 60 (40 %) for men and N = 18 (33 %) for
women (p = 0.418). Of the 53 patients that had HEV spe-
cific IgG antibodies at baseline, 46 had at least one
follow-up sample post-LT. Fifteen of these patients
(33 %) with IgG antibodies at baseline had IgG loss at
some point post-LT. A total of 125 patients had a base-
line sample and at least one follow up sample available.
Eight patients (6.4 %) were IgG negative at baseline and
showed IgG seroconversion post-LT; four at year 1, one
at year 3 and three at year 5 post-LT. Two of these eight
patients had IgG loss after post-LT seroconversion.
Pre-LT
N=145
1 yr post-LT
N=113
3 yr post-LT
N=65
5 yr post-LT
N=47
53 IgG+ (37%) 
5 IgM+ (3.4%) 
35 IgG+ (31%) 
2 IgM+ (1.8%)
14 IgG+ (22%)
2 IgM+ (3.1%)
19 IgG+ (40%)
2 IgM+ (4.3%)
Total 145 LT-recipients for HCV
(N=370 samples)
HEV serology
Fig. 1 Sample distribution and Hepatitis E serology in 145 Liver Transplant Recipients. Abbreviations: LT, Liver Transplant; HEV, Hepatitis E Virus
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Only six out of 145 patients (4.1 %) had IgM anti-
bodies against HEV. Five patients had IgG and IgM
antibodies against HEV at baseline and one patient,
who had been IgG positive from baseline up to 5 years
post-LT, seroconverted IgM at year 5 post-LT (see also
Table 2). One of the 6 IgM-positive patients had IgG
and IgM loss post-LT, another patient experienced IgG
loss but remained IgM positive.Post-LT HEV infection
None of the last available samples in the 145 patients or
any of the samples in the IgM positive and IgG serocon-
verters were positive for HEV RNA. We hypothesized
that HCV infected LT-recipients were protected against
chronic HEV infection due to concurrent treatment with
either (peg) interferon or RBV for the treatment of HCV.
To test this hypothesis we selected the patients that were
most likely to have had active infection post-LT, namely:
the patients that had IgM and/or IgG seroconversion
post-LT. All 8 IgG seroconverters and the single IgM posi-
tive patient that seroconverted after LT met this definition
and were further explored (see Table 2).Table 1 Baseline characteristics in LT recipients with a history of
HCV infection
HEV IgG positive
N = 53
HEV IgG negative
N = 92
p-value
Mean age, years 53 ± 7 51 ± 8 0.153
Male sex 45 (85 %) 64 (70 %) 0.047
Caucasian ethnicity 47 (88 %) 79 (84 %) 0.615
Residing in Minnesota 29 (53 %) 35 (37 %) 0.077
History of alcohol abuse 26 (49 %) 34 (37 %) 0.166
HCV genotype 1 28 (67 %) 63 (83 %) 0.066
LT liver transplant, HCV Hepatitis C virus, HEV Hepatitis E virusAll but one patient was treated with (peg) interferon
and/or RBV before or at the time of seroconversion.Discussion
In this study we examined the prevalence and impact
of serological evidence of HEV infection among a well-
defined cohort of US liver transplant recipients with a
history of HCV infection. The impact of HEV infection
among solid organ transplant recipients is likely to be
greatest among patients with pre-existing liver injury
such as caused by chronic HCV, since acute on chronic
infection will most likely lead to an aggravated clinical
course. Post-transplant HCV infection is the most com-
mon cause of graft loss among liver transplant recipients,
raising the possibility that the consequences of post-
transplant HEV infection might be most readily apparent
in this group of patients. Our analysis of HEV infection in
a relatively large cohort of liver transplant recipients with
HCV infection has produced several potentially important
results that merit detailed consideration. The first im-
portant observation is that in this cohort, more than
four out of ten liver transplant recipients with a history
of HCV infection have been in contact with HEV. This
finding highlights that these patients are at considerable
risk of exposure to HEV, which may lead to chronic in-
fection or accelerated liver disease. Indeed, we showed
that transplant recipients in the US are at risk of ac-
quiring HEV infection following liver transplantation,
considering that nine out of 125 patients (7.2 %) with at
least one follow up sample had HEV seroconversion
post-LT.
There are several explanations why over four out of
ten patients in this cohort of US liver transplant recipients
with a history of HCV infection have HEV antibodies.
Since HCV is a blood borne disease, HEV infection may
share the same transmission route as HCV. An association
between intravenous drug use in HCV infected patients
Table 2 Characteristics of nine post-LT HEV seroconverting patients with a history of HCV infection
Age at LT Gender Ethnicity LT year Type of serologic
conversion
Conversion
year (from LT)
Post-LT HCV
treatment
Treatment year
post-LT
Treatment
medication
Pt 1 46 Male Caucasian 1998 IgM 5 Yes 1-5 IFN + RBV
Pt 2 48 Male Caucasian 1998 IgG 1 Yes 0-1 IFN + RBV
Pt 3 39 Male Native Hawaiian 2000 IgG 5 Yes 2-3 IFN + RBV
Pt 4 36 Female Caucasian 2001 IgG 1 Yes 0-1 IFN + RBV
Pt 5 47 Male Other NS 2001 IgG 1 Yes 0 IFN
Pt 6 51 Male Caucasian 2001 IgG 5 Yes 2-4 IFN + RBV
Pt 7 47 Male Caucasian 2003 IgG 3 Yes 1-4 IFN + RBV
Pt 8 51 Male Caucasian 2004 IgG 5 Yes 0-3 IFN + RBV
Pt 9 54 Male Caucasian 2009 IgG 1 No N/A N/A
LT Liver transplant, HEV Hepatitis E virus, HCV Hepatitis C virus, IFN (peg) interferon, RBV ribavirin, Other NS Other than Caucasian, Hispanic, Black or Asian, not
specified, N/A not applicable
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inconsistently reported [25, 26]. Another possible trans-
mission route is through transfusion with blood products.
There is a considerable seroprevalence of HEV in blood
donors in the US with anti-HEV antibodies of up to 22 %,
though no active infection in US cohorts has been found
[9–11]. In contrast, in European cohorts, HEV RNA was
found in plasma and blood donors [27–33] leading to HEV
infection in patients receiving those blood components
[33]. As long as blood products are not routinely screened
for HEV RNA, US physicians should be aware of this pos-
sible transmission route. LT recipients usually have received
multiple blood products over the course of their disease.
HCV treated LT recipients are even more likely of receiv-
ing blood transfusion due to treatment-induced anemia,
further increasing the chance of receiving blood products
from an HEV viremic donor. Patients are also at risk of
acquiring HEV through infection of the donor organ as a
recent report on a liver transplant recipient showed [34].
Finally, the average age in this cohort was 51.8 years and
several studies have shown that HEV seroprevalence
increases with age [10, 11, 35, 36].
One of the unexpected observations in our analysis
was that, despite a substantial number of patients sero-
converting to anti-HEV IgM and/or anti-HEV IgG
following liver transplantation, we did not find any active
HEV infection in this cohort. It is possible that HEV
viremia was missed in our study due to the time be-
tween serum draws that were available for analysis. HEV
seroconversion may have occurred with (spontaneous)
clearance of active HEV infection and subsequent loss of
HEV antibodies over time due to immunosuppressive
therapy, as illustrated by HEV IgG loss post-LT in one
third of patients with HEV IgG antibodies at baseline.
We may also have missed patients that did not serocon-
vert at all despite infection due to their immunosuppres-
sive state, since HEV seroconversion is often delayed or
even absent in these patients [6, 24, 37, 38]. Patients thatobtained HEV infection after the last follow up sample
and subsequently died will have been missed as well.
Our results may, therefore, have underestimated the
severity of acute HEV infection.
We used the most sensitive HEV serologic test avail-
able at the moment [39–41] and an internally controlled
quantitative real-time RT-PCR, which has been an ef-
fective and reproducible tool for detecting HEV RNA
in other cohorts [35, 42]. The effects of immunosuppres-
sion, which include suppression of antibody production
and an increase of levels of viremia (e.g. for HCV, HBV,
CMV), may have resulted in an underestimation of the
seroprevalence of anti-HEV in this cohort but should
not have affected the numbers regarding prevalence of
active HEV infection. Our results should generally be
viewed as reassuring in that no active HEV infection
was found in any of the patients at last follow up.
Moreover, HEV infection in SOT recipients does not
always progress to chronicity [37]. A further consi-
deration in the lack of active HEV infection in our
analysis is that eight out of nine post-LT anti-HEV sero-
converters were treated with either RBV or (peg) inter-
feron. Both of these agents are known to be effective
therapies for HEV infection and may have contributed to
HEV clearance. As HCV treatment initiation is often
based on clinical parameters indicating (recurrent) hepa-
titis, it is possible that superinfection with HEV may have
contributed to the likelihood of initiation of anti-HCV
therapy. Soon, new antiviral agents, including interferon-
and ribavirin-free protocols, against HCV will become
available for the treatment of HCV infection. The dis-
appearance of interferon and RBV from HCV treatment
regimens may increase the risk of acquiring chronic HEV
and subsequent development of fibrosis and cirrhosis, as
these new agents will most likely not have activity against
HEV. HCV liver transplant recipients not treated for
HEV are currently still at risk of developing chronic
HEV.
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tive non-HCV infected group of liver transplant recipi-
ents, the retrospective nature of the study and patients
that were lost to follow up due to their transferring care
to a local hospital.
Conclusions
LT recipients in the US are at risk of acquiring HEV.
Therefore, screening of HEV in LT recipients should be
carried out routinely, especially when there are clinical
signs of (progressive) hepatitis. Evaluation of immuno-
compromised patients should include HEV RNA testing,
since antibody detection is often delayed in these pa-
tients. Due to the lack of FDA-approved HEV RNA tests
and high interlaboratory variability in PCR performance
[43], we recommend to have samples tested in a labora-
tory with extensive experience and up to date assays.
HCV infected LT recipients may be protected against
the development of chronic HEV through treatment
against HCV. However, HEV infection should be best
managed through dose reduction of immunosuppressive
medication and/or treatment with low-dose RBV [44],
avoiding overtreatment of HCV infected patients. Due
to the arrival of new interferon- and RBV-free HCV
regimens not active against HEV, HCV infected LT re-
cipients will again be at risk of acquiring (chronic) HEV
in the nearby future.
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